Long-term results after surgical resection of intrahepatic cholangiocarcinoma before and since the BILCAP era

BackgroundSince the first data of the BILCAP trial was presented in 2017, capecitabine became standard adjuvant treatment for intrahepatic cholangiocarcinoma (ICC). For ICC, the efficacy of capecitabine on survival outcomes remains unresolved as the BILCAP trial included all entities of biliary trac...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Fabian Bartsch, Constantin Scholz, Lisa-Katharina Gröger, Lara Bachmann, Janine Baumgart, Ann-Kathrin Lederer, Jens Mittler, Maria Hoppe-Lotichius, Beate K. Straub, Friedrich Foerster, Arndt Weinmann, Evangelos Tagkalos, Hauke Lang
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Frontiers Media S.A. 2026-06-01
Serie:	Frontiers in Surgery
Ämnen:	adjuvant therapy BILCAP capecitabine cholangiocarcinoma intrahepatic cholangiocarcinoma liver surgery
Länkar:	https://www.frontiersin.org/articles/10.3389/fsurg.2026.1853219/full
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!